Lead Story
2026 Nobel Prize in Medicine honors the scientists behind optogenetics
The Karolinska Institute announced on October 5 that Karl Deisseroth of Stanford, Peter Hegemann of Humboldt University Berlin, and Georg Nagel of the University of Würzburg had won the 2026 Nobel Prize in Physiology or Medicine for discovering light-gated ion channels and developing optogenetics. Hegemann and Nagel's research on how the alga Chlamydomonas swims toward light led them to identify channelrhodopsin, a light-sensitive protein channel; Nagel's follow-up experiments injecting the alga's genes into frog eggs uncovered channelrhodopsin-2. Deisseroth then showed the protein could switch individual neurons on or off in living rat brain tissue, and the technique was named optogenetics in 2006. The method has since become a cornerstone tool across neuroscience, letting researchers precisely control specific nerve cells to study memory, behavior and disease, and it is now being explored as a potential treatment approach in its own right.
Read more →Lead Story
2026 Nobel Prize in Medicine honors the scientists behind optogenetics
The Karolinska Institute announced on October 5 that Karl Deisseroth of Stanford, Peter Hegemann of Humboldt University Berlin, and Georg Nagel of the University of Würzburg had won the 2026 Nobel Prize in Physiology or Medicine for discovering light-gated ion channels and developing optogenetics. Hegemann and Nagel's research on how the alga Chlamydomonas swims toward light led them to identify channelrhodopsin, a light-sensitive protein channel; Nagel's follow-up experiments injecting the alga's genes into frog eggs uncovered channelrhodopsin-2. Deisseroth then showed the protein could switch individual neurons on or off in living rat brain tissue, and the technique was named optogenetics in 2006. The method has since become a cornerstone tool across neuroscience, letting researchers precisely control specific nerve cells to study memory, behavior and disease, and it is now being explored as a potential treatment approach in its own right.
New Zealand's kākāpō population tops 300 for the first time in roughly 75 years
New Zealand's Department of Conservation confirmed on September 1 that the kākāpō population has reached 325 birds after a record breeding season added 90 surviving chicks to the official count, the most chicks ever produced in a single season for the critically endangered flightless parrot. DOC noted it took 16 years for the programme, which began in 1995 with just 51 birds, to produce that many chicks in its early years combined. The boom followed a four-year gap between breeding seasons: kākāpō breed only when rimu trees fruit heavily, and an unusually abundant rimu crop on two predator-free breeding islands in Fiordland let females raise chicks without supplementary feeding. Programme manager Deidre Vercoe cautioned that challenges including low genetic diversity, infertility and poor hatching success mean a long recovery road remains, but called the milestone a major step for a species once reduced to just a few dozen individuals.
Read more →New Zealand's kākāpō population tops 300 for the first time in roughly 75 years
New Zealand's Department of Conservation confirmed on September 1 that the kākāpō population has reached 325 birds after a record breeding season added 90 surviving chicks to the official count, the most chicks ever produced in a single season for the critically endangered flightless parrot. DOC noted it took 16 years for the programme, which began in 1995 with just 51 birds, to produce that many chicks in its early years combined. The boom followed a four-year gap between breeding seasons: kākāpō breed only when rimu trees fruit heavily, and an unusually abundant rimu crop on two predator-free breeding islands in Fiordland let females raise chicks without supplementary feeding. Programme manager Deidre Vercoe cautioned that challenges including low genetic diversity, infertility and poor hatching success mean a long recovery road remains, but called the milestone a major step for a species once reduced to just a few dozen individuals.
FDA approves first gene therapy for Sanfilippo syndrome type A
The FDA granted full approval on September 17 to Fayuvi, Ultragenyx's one-time gene therapy for Sanfilippo syndrome type A (MPS IIIA), a rare and fatal pediatric neurodegenerative disorder, making it the first treatment to target the disease's underlying genetic cause rather than just its symptoms. The intravenous, AAV9-based therapy delivers a working copy of the SGSH gene, allowing the body to produce the enzyme sulfamidase and clear the toxic buildup that otherwise causes relentless cognitive decline in affected children. Approval rested on a study of patients aged two to five who maintained or improved cognitive function compared with an untreated historical control group, and came a year after the FDA had initially rejected the therapy over manufacturing issues. The approval gives families facing a previously untreatable diagnosis a real therapeutic option for the first time.
Read more →FDA approves first gene therapy for Sanfilippo syndrome type A
The FDA granted full approval on September 17 to Fayuvi, Ultragenyx's one-time gene therapy for Sanfilippo syndrome type A (MPS IIIA), a rare and fatal pediatric neurodegenerative disorder, making it the first treatment to target the disease's underlying genetic cause rather than just its symptoms. The intravenous, AAV9-based therapy delivers a working copy of the SGSH gene, allowing the body to produce the enzyme sulfamidase and clear the toxic buildup that otherwise causes relentless cognitive decline in affected children. Approval rested on a study of patients aged two to five who maintained or improved cognitive function compared with an untreated historical control group, and came a year after the FDA had initially rejected the therapy over manufacturing issues. The approval gives families facing a previously untreatable diagnosis a real therapeutic option for the first time.
Five more countries and territories eliminate major diseases across the Americas
The Pan American Health Organization announced on September 29 that it had recognized five countries and territories for newly eliminating or controlling diseases that have long burdened the region. Brazil was validated for eliminating mother-to-child transmission of HIV, as were the Bahamas and Turks and Caicos; Chile was recognized both for eliminating leprosy as a public health problem and for validating the absence of dog-transmitted rabies; and El Salvador was validated for eliminating trachoma, a bacterial infection that can cause blindness. The recognitions, awarded at PAHO's 63rd Directing Council, cover achievements certified between September 2025 and September 2026 and reflect sustained investment in vaccination, maternal screening and neglected-disease control programmes across the region, adding to a broader wave of WHO-validated eliminations worldwide this year.
Read more →Five more countries and territories eliminate major diseases across the Americas
The Pan American Health Organization announced on September 29 that it had recognized five countries and territories for newly eliminating or controlling diseases that have long burdened the region. Brazil was validated for eliminating mother-to-child transmission of HIV, as were the Bahamas and Turks and Caicos; Chile was recognized both for eliminating leprosy as a public health problem and for validating the absence of dog-transmitted rabies; and El Salvador was validated for eliminating trachoma, a bacterial infection that can cause blindness. The recognitions, awarded at PAHO's 63rd Directing Council, cover achievements certified between September 2025 and September 2026 and reflect sustained investment in vaccination, maternal screening and neglected-disease control programmes across the region, adding to a broader wave of WHO-validated eliminations worldwide this year.
Wind and solar outproduced gas in global electricity generation for the first time
Energy think tank Ember reported in May that wind and solar together generated more electricity worldwide than natural gas for the first time in a single month, with April 2026 output reaching a record 531 terawatt-hours against 477 terawatt-hours from gas. Combined wind and solar accounted for 22% of global electricity generation that month, edging past gas's 20% share, a dramatic shift from April 2021, when gas output was roughly double that of wind and solar combined. Ember said global wind and solar generation grew about 13% year-on-year, with China, the European Union, the UK and the US among the markets driving the gains, and found no evidence that the milestone came from countries switching from gas back to coal. While the think tank cautioned the crossover held for only one month rather than a full year, it framed the result as part of a sustained structural trend in the global power mix rather than a one-off reaction to energy-market turmoil.
Read more →Wind and solar outproduced gas in global electricity generation for the first time
Energy think tank Ember reported in May that wind and solar together generated more electricity worldwide than natural gas for the first time in a single month, with April 2026 output reaching a record 531 terawatt-hours against 477 terawatt-hours from gas. Combined wind and solar accounted for 22% of global electricity generation that month, edging past gas's 20% share, a dramatic shift from April 2021, when gas output was roughly double that of wind and solar combined. Ember said global wind and solar generation grew about 13% year-on-year, with China, the European Union, the UK and the US among the markets driving the gains, and found no evidence that the milestone came from countries switching from gas back to coal. While the think tank cautioned the crossover held for only one month rather than a full year, it framed the result as part of a sustained structural trend in the global power mix rather than a one-off reaction to energy-market turmoil.